NASDAQ listed ObsEva raises USD 60 million in PIPE transaction

NASDAQ listed ObsEva SA, a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health, entered into a private investment in public equity (PIPE) transaction with new and existing investors. The transaction is expected to yield gross proceeds of USD 60 million. Lenz & Staehelin acts as Swiss counsel to ObsEva SA.

The Lenz & Staehelin team is led by Jacques Iffland (Partner, Corporate and M&A) and includes associates Danusha Nacht and Ariel Ben Hattar (both Corporate and M&A).